Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Rezolute, Inc. stock logo
RZLT
Rezolute
$4.60
$4.76
$1.07
▼
$11.46
$442.94M0.581.22 million shs657,066 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Rezolute, Inc. stock logo
RZLT
Rezolute
0.00%-1.92%+5.26%+37.72%-28.90%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Rezolute, Inc. stock logo
RZLT
Rezolute
$4.60
$4.76
$1.07
▼
$11.46
$442.94M0.581.22 million shs657,066 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Rezolute, Inc. stock logo
RZLT
Rezolute
0.00%-1.92%+5.26%+37.72%-28.90%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Rezolute, Inc. stock logo
RZLT
Rezolute
2.50
Moderate Buy$9.38103.80% Upside

Current Analyst Ratings Breakdown

Latest RZLT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/30/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/17/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/16/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
6/15/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$6.00 ➝ $11.00
6/3/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
6/3/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform
6/3/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$11.00
6/3/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$5.00 ➝ $6.00
6/2/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$5.00 ➝ $6.00
6/2/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
Maxim Group logo
Maxim Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$10.00 ➝ $14.00
(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Rezolute, Inc. stock logo
RZLT
Rezolute
N/AN/AN/AN/A$1.86 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Rezolute, Inc. stock logo
RZLT
Rezolute
-$74.41M-$0.82N/AN/AN/AN/A-58.82%-54.48%9/16/2026 (Estimated)
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Rezolute, Inc. stock logo
RZLT
Rezolute
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Rezolute, Inc. stock logo
RZLT
Rezolute
N/A
15.84
15.84

Institutional Ownership

CompanyInstitutional Ownership
Rezolute, Inc. stock logo
RZLT
Rezolute
82.97%

Insider Ownership

CompanyInsider Ownership
Rezolute, Inc. stock logo
RZLT
Rezolute
14.78%
CompanyEmployeesShares OutstandingFree FloatOptionable
Rezolute, Inc. stock logo
RZLT
Rezolute
4096.29 million82.06 millionOptionable

Recent News About These Companies

Rezolute, Inc. $RZLT Shares Acquired by Dimensional Fund Advisors LP
August 14 at 3:28 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-rezolute-inc-rzlt-shares-acquired-by-dimensional-fund-advisors-lp-2026-08-14/
Analysts Offer Insights on Healthcare Companies: Rezolute (RZLT) and Boston Scientific (BSX)
July 30, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RZLT/pressreleases/3559521/analysts-offer-insights-on-healthcare-companies-rezolute-rzlt-and-boston-scientific-bsx/
Rezolute, Inc. (NASDAQ:RZLT) Receives Consensus Recommendation of "Moderate Buy" from Analysts
July 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/rezolute-inc-nasdaqrzlt-receives-consensus-recommendation-of-moderate-buy-from-analysts-2026-07-25/
Affinity Asset Advisors LLC Sells 803,503 Shares of Rezolute, Inc. $RZLT
July 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-affinity-asset-advisors-llc-sells-803503-shares-of-rezolute-inc-rzlt-2026-07-25/
Siren L.L.C. Acquires New Position in Rezolute, Inc. $RZLT
July 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-siren-llc-acquires-new-position-in-rezolute-inc-rzlt-2026-07-24/
Jennison Associates LLC Buys New Position in Rezolute, Inc. $RZLT
July 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-jennison-associates-llc-buys-new-position-in-rezolute-inc-rzlt-2026-07-22/
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
July 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/21/3330330/0/en/rezolute-to-participate-in-the-btig-virtual-biotechnology-conference.html
Rezolute (NASDAQ:RZLT) Cut to "Strong Sell" at Zacks Research
July 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/rezolute-nasdaqrzlt-cut-to-strong-sell-at-zacks-research-2026-07-18/
Rezolute Inc.
June 29, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/rzlt/financials/cash-flow
FDA Grants Orphan Drug Designation to Rezolute's Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
June 25, 2026  |  stockhouse.comhttps://stockhouse.com/news/press-releases/2024/12/03/fda-grants-orphan-drug-designation-to-rezolute-s-ersodetug-rz358-for-the
Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society
June 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/17/3313313/0/en/rezolute-highlights-results-presented-from-natural-history-outcomes-studies-and-its-ersodetug-clinical-program-in-hyperinsulinism-at-annual-meeting-of-the-endocrine-society.html
Analysts Offer Insights on Healthcare Companies: Rezolute (RZLT) and Vericel (VCEL)
June 12, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/VCEL/pressreleases/2413956/analysts-offer-insights-on-healthcare-companies-rezolute-rzlt-and-vericel-vcel/
Positive Signs As Multiple Insiders Buy Rezolute Stock
June 10, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/positive-signs-multiple-insiders-buy-114623068.html
RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week?
June 4, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2932573/rzlt-stock-on-the-move-what-sparks-the-38-jump-in-the-past-week?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2932573
Rezolute, Inc. Announces Four Presentations at the 2026 Annual Meeting of the Endocrine Society on Ersodetug for Congenital Hyperinsulinism
June 4, 2026  |  quiverquant.comQ
Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society
June 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/04/3306662/0/en/rezolute-announces-four-presentations-at-the-upcoming-annual-meeting-of-the-endocrine-society.html
Analysts Are Bullish on These Healthcare Stocks: Rezolute (RZLT), Relay Therapeutics (RLAY)
June 3, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/2289594/analysts-are-bullish-on-these-healthcare-stocks-rezolute-rzlt-relay-therapeutics-rlay/
Rezolute upgraded at Citizens after late-stage trial data for lead asset
June 3, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4600338-rezolute-upgraded-citizens-lead-asset
Rezolute rises after late-stage trial update
June 3, 2026  |  msn.comhttps://www.msn.com/en-us/health/general/rezolute-rises-after-late-stage-trial-update/ar-AA24F54O
Rezolute Highlights Strong Early Response Trends In Rare Hypoglycemia Disease Study
June 2, 2026  |  benzinga.comhttps://www.benzinga.com/markets/biotech/26/06/52947702/rezolute-highlights-strong-early-response-trends-in-rare-hypoglycemia-disease-study?utm_source=snapi
Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
June 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/02/3305007/0/en/rezolute-announces-positive-interim-data-for-its-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Rezolute stock logo

Rezolute NASDAQ:RZLT

$4.60 0.00 (0.00%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$4.60 0.00 (-0.11%)
As of 08/14/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas